Spanish singer Helena Bianco dies at 78 of neuroendocrine cancer

By Grace Kim

Helena Bianco, a central figure in Spanish pop during the 1960s and 1970s, died on Thursday the 12th at age 78 from neuroendocrine cancer. Her brother Alberto Vázquez, also a musician, confirmed her death.

Bianco’s career included the group Los Mismos, where she became an emblematic voice of the genre. Her path placed her among the central figures of Spanish pop across two decades.

She also found renewed visibility recently by winning La Voz Senior, a television program. The victory brought renewed public attention to a performer whose career was anchored in Spanish pop’s earlier decades.

What does the La Voz Senior win change for her legacy?

For audiences, the practical change is visibility. Bianco’s late-career public profile now includes a television victory alongside her work with Los Mismos. It gives renewed attention to a career first identified with Spanish pop in the 1960s and 1970s.

No broadcast date was reported for the victory. The chronology therefore cannot place the win before or after the September performance or November health disclosure. It establishes renewed recognition late in her life, but not its exact position within the final months.

Her final documented months

• September 15: Bianco made her last public appearance, performing in Bembibre, a city in León province. No venue, repertoire or audience details were reported.
• November 2: Her family said in an Instagram post that she was facing health problems and would undergo chemotherapy sessions. The family did not disclose the nature of the illness.
• Thursday the 12th: Alberto Vázquez confirmed her death at 78 from neuroendocrine cancer, following the clinical developments reported in the preceding weeks.

The chronology reveals how the news reached the public in stages. A live performance came first, then an announcement of treatment but not diagnosis. Vázquez’s confirmation named the disease and supplied the clinical fact absent from the family’s earlier post.

Bianco’s final performance offers a firm endpoint, but a narrow one. The report supports the date, city and province; it does not show what she performed or who attended. Any account of that evening should keep those limits rather than fill them with assumption.

The same discipline applies to her illness timeline. On November 2, the confirmed information was health problems and planned chemotherapy. The source identifies neuroendocrine cancer only when Vázquez confirms the death. That sequence explains how much the public knew, and when.

Future tributes and career assessments can now anchor Bianco’s final months in those three documented events, with neuroendocrine cancer named by her brother and the chemotherapy disclosure made by her family.